ETNB Rentabilitas dodolan miturut bathi reged 89bio Corp

Simbol resmi perusahaan 89bio Inc (ETNB)

89bio, Inc. (ETNB) is developing a therapy for the treatment of NASH, targeting the multi-billion dollar hepatology market. The gross profit margin demonstrates effective cost management, and its current value is 0.00. High investor confidence is bolstered by the company's scientific achievements in combating metabolic dysfunction. However, geopolitical instability and sanctions could slow drug synthesis and disrupt clinical trial timelines.

89bio (ETNB): Tingkat bathi reged saka 04.07.2022 nganti 15.11.2025

Rincian metrik keuangan lan pasar 89bio.com (ETNB)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis dhasar perusahaan:ETNB 89bio Corp
Produk dadi 89bio, Inc.

Gross margin measures the portion of revenue remaining after covering direct production costs, allowing for an assessment of the fundamental efficiency of profit generation per unit of product. By analyzing the gross margin ratio, an investor can discern the pricing power potential of 89bio, Inc., driven by the uniqueness of its liver fibrosis therapy and the lack of available alternatives, which renders demand inelastic and guarantees high sales profitability.